Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
http://www.reportlinker.com/p0946318/Chronic-Heart-Failure-CHF-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
Scope- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Heart Failure Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chronic Heart Failure Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Heart Failure Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chronic Heart Failure Therapeutics market
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Chronic Heart Failure Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Heart Failure Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Chronic Heart Failure Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Chronic Heart Failure Therapeutics - Introduction 7
2.1 Overview 7
2.2 Etiology 8
2.3 Pathophysiology 10
2.4 Epidemiology and Prognosis 12
2.5 Symptoms 13
2.6 Diagnosis 13
2.7 Treatment and Management Pattern 18
2.7.1 Pharmacological Therapies 18
2.7.2 Treatment Goals for Patients with Heart Failure 18
2.8 GlobalData Report Guidance 20
3 Chronic Heart Failure Therapeutics - Market Characterization 21
3.1 Chronic Heart Failure Therapeutics Market Size (2006-2011) - Global 21
3.2 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Global 22
3.3 Chronic Heart Failure Therapeutics Market Size (2006-2011) - The US 23
3.4 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - The US 24
3.5 Chronic Heart Failure Therapeutics Market (2006-2011) - France 25
3.6 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - France 26
3.7 Chronic Heart Failure Therapeutics Market (2006-2011) - Germany 27
3.8 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Germany 28
3.9 Chronic Heart Failure Therapeutics Market (2006-2011) - Italy 29
3.10 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Italy 30
3.11 Chronic Heart Failure Therapeutics Market (2006-2011) - Spain 31
3.12 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Spain 32
3.13 Chronic Heart Failure Therapeutics Market (2006-2011) - The UK 33
3.14 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - The UK 34
3.15 Chronic Heart Failure Therapeutics Market (2006-2011) - Japan 35
3.16 Chronic Heart Failure Therapeutics Market Forecast (2011-2019) - Japan 36
3.17 Drivers and Barriers for the Chronic Heart Failure Therapeutics Market 37
3.17.1 Drivers for the Chronic Heart Failure Therapeutics Market 37
3.17.2 Barriers for the Chronic Heart Failure Therapeutics Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 Key Takeaway 39
4 Chronic Heart Failure Therapeutics - Competitive Assessment 40
4.1 Overview 40
4.2 Strategic Competitor Assessment 40
4.3 Product Profile for the Major Marketed Products in the Chronic Heart Failure Therapeutics Market 41
4.3.1 Beta-adrenergic Receptor Blockers (Beta Blockers) 41
4.3.2 Coreg (carvedilol) 41
4.3.3 Altace (ramipril) 42
4.3.4 Diovan (valsartan) 43
4.4 Key Takeaway 44
5 Chronic Heart Failure Therapeutics - Pipeline Assessment 45
5.1 Overview 45
5.2 Strategic Pipeline Assessment 45
5.3 Chronic Heart Failure Therapeutics Pipeline - Pipeline by Phase of Development 45
5.3.1 Chronic Heart Failure Therapeutics - Phase III Pipeline 46
5.3.2 Chronic Heart Failure Therapeutics - Phase II Pipeline 46
5.3.3 Chronic Heart Failure Therapeutics - Phase I Pipeline 47
5.3.4 Chronic Heart Failure Therapeutics - Preclinical Pipeline 47
5.3.5 Chronic Heart Failure Therapeutics - Discovery Pipeline 47
5.4 Chronic Heart Failure Therapeutics Market - Clinical Pipeline by Mechanism of Action 48
5.5 Technology Trends Analytical Framework 49
5.6 Chronic Heart Failure Therapeutics - Promising Drugs Under Clinical Development 50
5.7 Molecule Profile for Phase III Drugs Under Clinical Development 51
5.7.1 LCZ696 51
5.7.2 Lixivaptan 51
5.7.3 Tekturna/Rasilez (aliskiren) 52
5.7.4 Aranesp 52
5.8 Key Takeaway 53
6 Chronic Heart Failure Therapeutics - Clinical Trials Mapping 54
6.1 Clinical Trials by Region/Country (The US, EU5, and Japan) 54
6.2 Clinical Trials by Phase 55
6.3 Clinical Trials by Trial Status 56
6.4 Clinical Trials by Overall Sponsors 57
6.5 Prominent Sponsors 58
6.6 Key Companies Participating in Therapeutics Clinical Trials 59
7 Chronic Heart Failure Therapeutics - Strategic Assessment 60
7.1 Key Events Impacting the Future Market 60
7.2 Chronic Heart Failure Therapeutics: Implications for Future Market Competition 61
8 Chronic Heart Failure Therapeutics - Future Players 62
8.1 Introduction 62
8.2 Company Profiles 63
8.2.1 Novartis AG. 63
8.2.2 Amgen Inc. 65
8.2.3 Cardiokine, Inc 66
8.2.4 Bayer AG. 67
8.2.5 Nile Therapeutics, Inc. 68
8.2.6 Cardioxyl Pharmaceuticals, Inc 69
8.2.7 Cytokinetics, Inc 70
8.2.8 GlaxoSmithKline plc 71
8.2.9 Trevena, Inc. 72
9 Chronic Heart Failure Therapeutics - Licensing and Partnership Deals 73
10 Chronic Heart Failure Therapeutics - Appendix 74
10.1 Market Definitions 74
10.2 Acronyms 74
10.3 Research Methodology 75
10.3.1 Coverage 76
10.3.2 Secondary Research 76
10.3.3 Forecasting 76
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 79
10.4 Contact Us 79
10.5 Disclaimer 79
10.6 Bibliography 80
List of Tables
Table 1: Clinical Condition in Chronic Heart Failure 7
Table 2: Classification of Heart Failure by Structural Abnormality (ACC/AHA), or by Symptoms Relating to Functional Capacity (NYHA) 8
Table 3: Common Causes of Heart Failure due to Disease of Heart Muscle (Myocardial Disease) 8
Table 4: Cause and Precipitating Factor in Chronic Heart Failure 9
Table 5: Assessment of Congestion 10
Table 6: Common Electrocardiography Abnormalities in CHF 13
Table 7: Common Chest X-ray Abnormalities in Chronic Heart Failure 14
Table 8: Common Laboratory Test Abnormalities in Chronic Heart Failure 15
Table 9: Common Echocardiographic Abnormalities in Chronic Heart Failure 17
Table 10: Chronic Heart Failure Therapeutics Market, Global, Revenue, $m, 2006-2011 21
Table 11: Chronic Heart Failure Therapeutics Market, Global, Forecast, $m, 2011-2019 22
Table 12: Chronic Heart Failure Therapeutics Market, The US, Revenue ($m), 2006-2011 23
Table 13: Chronic Heart Failure Therapeutics Market, The US, Forecast ($m), 2011-2019 24
Table 14: Chronic Heart Failure Therapeutics Market, France, Revenue ($m), 2006-2011 25
Table 15: Chronic Heart Failure Therapeutics Market, France, Forecast ($m), 2011-2019 26
Table 16: Chronic Heart Failure Therapeutics Market, Germany, Revenue ($m), 2006-2011 27
Table 17: Chronic Heart Failure Therapeutics Market, Germany, Forecast ($m), 2011-2019 28
Table 18: Chronic Heart Failure Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Table 19: Chronic Heart Failure Therapeutics Market, Italy, Forecast, $m, 2011-2019 30
Table 20: Chronic Heart Failure Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
Table 21: Chronic Heart Failure Therapeutics Market, Spain, Forecast ($m), 2011-2019 32
Table 22: Chronic Heart Failure Therapeutics Market, The UK, Revenue ($m), 2006-2011 33
Table 23: Chronic Heart Failure Therapeutics Market, the UK, Forecast ($m), 2011-2019 34
Table 24: Chronic Heart Failure Therapeutics Market, Japan, Revenue ($m), 2006-2011 35
Table 25: Chronic Heart Failure Therapeutics Market, Japan, Forecast ($m), 2011-2019 36
Table 26: Major Marketed Products in the Chronic Heart Failure Market, 2011 44
Table 27: Chronic Heart Failure Therapeutics Market - Phase III Pipeline, 2011 46
Table 28: Chronic Heart Failure Therapeutics Market - Phase II Pipeline, 2011 46
Table 29: Chronic Heart Failure Therapeutics Market - Phase I Pipeline, 2011 47
Table 30: Chronic Heart Failure Therapeutics Market - Preclinical Pipeline, 2011 47
Table 31: Chronic Heart Failure Therapeutics Market - Discovery Pipeline, 2011 47
Table 32: Chronic Heart Failure - Most Promising Drugs Under Clinical Development, 2011 50
Table 33: Chronic Heart Failure Therapeutics Market, Clinical Trials by Region, 2011 54
Table 34: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 55
Table 35: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 56
Table 36: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 57
Table 37: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 58
Table 38: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Lead Sponsors, 2011 59
Table 39: Pipeline Molecules 2011 64
Table 40: Pipeline Molecules 2011 66
Table 41: Pipeline Molecules 2011 66
Table 42: Pipeline Products 2011 68
Table 43: Pipeline Products 2011 69
Table 44: Pipeline Products 2011 69
Table 45: Pipeline Products 2011 71
Table 46: Product Pipeline 2011 72
Table 47: Pipeline Products 2011 72
Table 48: Licensing and Partnership Deals 73
List of Figures
Figure 1: Pathophysiology of Chronic Heart Failure 12
Figure 2: Treatment Algorithm for Acute Heart Failure with Systolic Dysfunction 19
Figure 3: Treatment Algorithm for Heart Failure 19
Figure 4: Chronic Heart Failure Therapeutics Market, Global, Revenue ($m), 2006-2011 21
Figure 5: Chronic Heart Failure Therapeutics Market, Global, Forecast ($m), 2011-2019 22
Figure 6: Chronic Heart Failure Therapeutics Market, The US, Revenue ($m), 2006-2011 23
Figure 7: Chronic Heart Failure Therapeutics Market, The US, Forecast ($m), 2011-2019 24
Figure 8: Chronic Heart Failure Therapeutics Market, France, Revenue ($m), 2006-2011 25
Figure 9: Chronic Heart Failure Therapeutics Market, France, Forecast ($m), 2011-2019 26
Figure 10: Chronic Heart Failure Therapeutics Market, Germany, Revenue ($m), 2006-2011 27
Figure 11: Chronic Heart Failure Therapeutics Market, Germany, Forecast ($m), 2011-2019 28
Figure 12: Chronic Heart Failure Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Figure 13: Chronic Heart Failure Therapeutics Market, Italy, Forecast ($m), 2011-2019 30
Figure 14: Chronic Heart Failure Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
Figure 15: Chronic Heart Failure Therapeutics Market, Spain, Forecast ($m), 2011-2019 32
Figure 16: Chronic Heart Failure Therapeutics Market, The UK, Revenue ($m), 2006-2011 33
Figure 17: Chronic Heart Failure Therapeutics Market, The UK, Forecast ($m), 2011-2019 34
Figure 18: Chronic Heart Failure Therapeutics Market, Japan, Revenue ($m), 2006-2011 35
Figure 19: Chronic Heart Failure Therapeutics Market, Japan, Forecast ($m), 2011-2019 36
Figure 20: Opportunity and Unmet Need in the Chronic Heart Failure Therapeutics Market, 2011 38
Figure 21: Opportunity and Unmet Need in the Chronic Heart Failure Therapeutics Market, 2011 40
Figure 22: Chronic Heart Failure Therapeutics Pipeline by Phase of Clinical Development, 2011 45
Figure 23: Chronic Heart Failure Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 48
Figure 24: Technology Trends Analytic Framework for the Chronic Heart Failure Therapeutics Pipeline, 2011 49
Figure 25: Technology Trends Analytic Framework for the Chronic Heart Failure Therapeutics Pipeline, 2011 50
Figure 26: Chronic Heart Failure Therapeutics Market - Clinical Trials by Region, 2011 54
Figure 27: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Phase of Development, 2011 55
Figure 28: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Trial Status, 2011 56
Figure 29: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Overall Sponsors, 2011 57
Figure 30: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Prominent Sponsors, 2011 58
Figure 31: Chronic Heart Failure Therapeutics Market, Global, Clinical Trials by Top Companies, 2011 59
Figure 32: Drivers and Barriers of the Chronic Heart Failure Therapeutics Market 60
Figure 33: Implications for Future Market Competition in the Chronic Heart Failure Therapeutics Market, 2011 61
Figure 34: Chronic Heart Failure Therapeutics Market - Clinical Pipeline by Company, 2011 62
Figure 35: GlobalData Market Forecasting Model 78
Companies Mentioned
Amgen Inc.
Cardiokine, Inc
Bayer AG.
Nile Therapeutics, Inc.
Cardioxyl Pharmaceuticals, Inc
Cytokinetics, Inc
GlaxoSmithKline plc
Trevena, Inc.
To order this report:: Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article